Highlights from EAU 2017 - Results from #80

Viewing 81-100 of 138 articles

EAU 2017: At what age should a PSA-based screening program start? 20-year results from the Göteborg randomized population-based prostate cancer screening study

EAU 2017: An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial

EAU 2017: APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

EAU 2017: A national, prospective, non-interventional study (NIS) of nivolumab (BMS-936558) in patients with advanced renal cell carcinoma after prior therapy

EAU 2017: IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC)

EAU 2017: PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)

EAU 2017: Phase 1b/2 trial of pembrolizumab combination therapy for metastatic castration-resistant prostate cancer (mCRPC)

EAU 2017: Does imaging improve safety and efficacy of primary and salvage radiotherapy?

EAU 2017: When and how to include MRI into active surveillance protocols?

EAU 2017: Controversies - Focal therapy and the concept of the index lesion: Nonsense

EAU 2017: Controversies - Focal therapy and the concept of the index lesion: Sense

EAU 2017: Comparison effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder

EAU 2017: Can radical cystectomy be performed safely in the metastatic setting? Location of metastatic bladder cancer as a determinant of in-hospital mortality

EAU 2017: EANM Lecture: Is Choline PET Outdated?

EAU 2017: PSMA at Initial Staging

EAU 2017: How to define ‘significant’ disease on targeted biopsy

EAU 2017: Controversies: What helps more to characterize the disease? Biomarkers and Genetic Profiling

EAU 2017: Controversies: What helps more to characterize the disease? Imaging

EAU 2017: Controversies in prostate cancer detection: Biparametric MRI is enough

EAU 2017: Controversies in prostate cancer detection: Multiparametric MRI is a must

1
2
3
4
5
6
7